Rapport Therapeutics (RAPP) had its price target raised by Wells Fargo & Company from $43.00 to $46.00. They now have an "overweight" rating on the stock.
Rapport Therapeutics (RAPP) had its "market outperform" rating reaffirmed by Citigroup Inc..
Rapport Therapeutics GAAP EPS of -$0.72 misses by $0.03 [Seeking Alpha]
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update